SEC Form 4 · accession 0001385508-19-000006
OPIANT PHARMACEUTICALS, INC. · OPNT
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
David D O'Toole
Officer — Chief Financial Officer
Period of report
Jan 3, 2019
Accepted (ET)
Jan 4, 2019 · 5:18 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001385508
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1 | $13.61 | Jan 3, 2019 | A | 33,000 | A | — | Jan 2, 2029 | Common Stock | 33,000 | 33,000 | D |
Explanation of responses
- F1On January 3, 2019, the reporting person was granted an option to purchase 33,000 shares of common stock. The option vests as follows: 1/48 of the options become exercisable on the first monthly anniversary of the vesting commencement date, and 1/48 of the options become exercisable on such date every month thereafter through the fourth anniversary of the Grant Date.